Current status of nano‐vaccinology in veterinary medicine science

Abstract Vaccination programmes provide a safe, effective and cost‐efficient strategy for maintaining population health. In veterinary medicine, vaccination not only reduces disease within animal populations but also serves to enhance public health by targeting zoonoses. Nevertheless, for many pathogens, an effective vaccine remains elusive. Recently, nanovaccines have proved to be successful for various infectious and non‐infectious diseases of animals. These novel technologies, such as virus‐like particles, self‐assembling proteins, polymeric nanoparticles, liposomes and virosomes, offer great potential for solving many of the vaccine production challenges. Their benefits include low immunotoxicity, antigen stability, enhanced immunogenicity, flexibility sustained release and the ability to evoke both humoral and cellular immune responses. Nanovaccines are more efficient than traditional vaccines due to ease of control and plasticity in their physio‐chemical properties. They use a highly targeted immunological approach which can provide strong and long‐lasting immunity. This article reviews the currently available nanovaccine technology and considers its utility for both infectious diseases and non‐infectious diseases such as auto‐immunity and cancer. Future research opportunities and application challenges from bench to clinical usage are also discussed.